Mosby's 2014 Nursing Drug Reference (230 page)

BOOK: Mosby's 2014 Nursing Drug Reference
8.54Mb size Format: txt, pdf, ePub

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

Ketotifen (ophthalmic)

(kee-toe-tye′fen)

Alaway, Zaditor, Zyrtec Itchy Eye, Claritin Eye

Func. class.:
Antihistamine (ophthalmic)

Chem. class.:
Histamine 1 receptor antagonist/mast cell stabilizer

ACTION:

A topically active, direct H
1
- receptor antagonist and mast cell stabilizer; by reducing these inflammatory mediators, relieves the ocular pruritus associated with allergic conjunctivitis

USES:

For the temporary relief of ocular pruritus due to ragweed, pollen, grass, animal hair, animal dander

CONTRAINDICATIONS:

Hypersensitivity

Precautions:
Pregnancy (C), breastfeeding, children, contact lenses

DOSAGE AND ROUTES
Calculator

• Adult/child

3 yr:
OPHTH instill 1 drop in affected eye(s) every 8-12 hr

Available forms:
Ophthalmic solution 0.025%

Administer:
Ophthalmic route

• 
For topical ophthalmic use only

• 
Wash hands before and after use; tilt the head back slightly and pull the lower eyelid down with the index finger; squeeze the prescribed number of drops into the conjunctival sac and gently close eyes for 1–2 min, do not blink

• 
Do not touch the tip of the dropper to the eye, fingertips, or other surface

• 
Wait ≥10 min after instilling the ophthalmic solution before inserting contact lenses; contact lenses should not be worn if eye is red

• 
Do not share ophthalmic drops with others

SIDE EFFECTS

CNS:
Headache

EENT:
Conjunctival hyperemia, rhinitis, allergic reactions, ocular irritation consisting of burning or stinging, conjunctivitis, eyelid disorder, flu syndrome, keratitis, lacrimation disorder, mydriasis, ocular discharge, ocular pain, pharyngitis, photophobia, pruritus, rash, xerophthalmia (dry eyes)

NURSING CONSIDERATIONS
Assess:

• 
Eyes: for itching, redness, use of soft or hard contact lens

Evaluate:

• 
Absence of redness, itching in the eyes

Teach patient/family:
Ophthalmic route

• 
That product is for topical ophthalmic use only

• 
To wash hands before and after use; tilt the head back slightly and pull the lower eyelid down with the index finger; squeeze the prescribed number of drops into the conjunctival sac and gently close eyes for 1–2 min; not to blink

• 
Not to touch the tip of the dropper to the eye, fingertips, or other surface

• 
To wait ≥10 min after instilling the ophthalmic solution before inserting contact lenses; contact lenses should not be worn if eye is red

• 
Not to share ophthalmic drops with others

• 
To remove contact lenses before use because the preservative benzalkonium chloride may be absorbed by soft contact lenses; that product should not be used to treat contact lens–related irritation

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

labetalol (Rx)

(la-bet′a-lole)

Trandate

Func. class.:
Antihypertensive, antianginal

Chem. class.:
α-1/β-Blocker

Do not confuse:
Trandate
/Tridrate

ACTION:

Produces decreases in B/P without reflex tachycardia or significant reduction in heart rate through mixture of α-blocking, β-blocking effects; elevated plasma renins are reduced

USES:

Mild to moderate hypertension; treatment of severe hypertension (IV)

Unlabeled uses:
Hypertension in patients with pheochromocytoma, hypertension during cloNIDine withdrawal, pediatric hypertension

CONTRAINDICATIONS:

Hypersensitivity to β-blockers, cardiogenic shock, heart block (2nd or 3rd degree), sinus bradycardia, CHF, bronchial asthma

Precautions:
Pregnancy (C), breastfeeding, geriatric patients, major surgery, diabetes mellitus, thyroid/renal/hepatic disease, COPD, well-compensated heart failure, CAD, nonallergic bronchospasm, peripheral vascular disease

 

Black Box Warning:

Abrupt discontinuation

DOSAGE AND ROUTES
Calculator
Hypertension

• Adult:
PO
100 mg bid; may be given with diuretic; may increase to 200 mg bid after 2 days; may continue to increase q1-3days; max 2400 mg/day in divided doses

• Child/adolescent (unlabeled):
PO
1-3 mg/kg/day, titrate to max 10-20 mg/kg/day based on B/P;
IV
0.2-1 mg/kg over 2 min, max 40 mg/dose;
IV INF
0.25-3 mg/kg/hr

Hypertensive crisis

• Adult:
IV INF
200 mg/160 ml D
5
W, run at 2 mg/min or 1.6 ml/min; stop inf at desired response, repeat q6-8hr as needed;
IV BOL
20-80 mg over 2 min, may repeat q10min, not to exceed 300 mg

Available forms:
Tabs 100, 200, 300 mg; inj 5 mg/ml

Administer:

• 
PO before meals, at bedtime; tab may be crushed or swallowed whole; give with meals to increase absorption

• 
Reduced dosage for renal dysfunction

• 
Do not discontinue before surgery

Direct IV route

• 
Give undiluted (5 mg/ml) over 2 min

Continuous IV INF route

• 
Diluted in LR, D
5
W, D
5
in 0.2%, 0.9%, 0.33% NaCl, Ringer’s inj; inf is titrated to patient response; 200 mg of product/160 ml sol = 1 mg/ml; 300 mg of product/240 ml sol = 1 mg/ml; 200 mg of product/250 ml sol = 2 mg/3 ml; use inf pump

• 
Keep patient recumbent during and for 3 hr after administration; monitor VS q5-15min

Y-site compatibilities:
Amikacin, aminophylline, amiodarone, ampicillin, butorphanol, calcium gluconate, cefTAZidime, ceftizoxime, cimetidine, diltiazem, DOBUTamine, DOPamine, enalaprilat, EPINEPHrine, erythromycin, esmolol, famotidine, fentaNYL, gentamicin, HYDROmorphone, lidocaine, LORazepam, magnesium sulfate, meperidine, metroNIDAZOLE, midazolam, milrinone, morphine, niCARdipine, nitroglycerin, norepinephrine, nitroprusside, oxacillin, potassium chloride, potassium phosphate, propofol, ranitidine, sodium acetate, tobramycin, vancomycin, vecuronium

SIDE EFFECTS

CNS:
Dizziness, mental changes, drowsiness, fatigue, headache, catatonia, depression, anxiety, nightmares, paresthesias, lethargy

CV:
Orthostatic hypotension, bradycardia
,
CHF,
chest pain,
ventricular dysrhythmias,
AV block, scalp tingling

EENT:
Tinnitus
, visual changes; sore throat; double vision; dry, burning eyes, floppy iris syndrome

GI:
Nausea, vomiting, diarrhea
, dyspepsia, taste distortion

GU:
Impotence, dysuria, ejaculatory failure

HEMA:
Agranulocytosis, thrombocytopenia, purpura
(rare)

INTEG:
Rash, alopecia, urticaria, pruritus, fever,
exfoliative dermatitis

RESP:
Bronchospasm,
dyspnea, wheezing

PHARMACOKINETICS

Half-life 2.5-8 hr, metabolized by liver (metabolites inactive), excreted in urine, crosses placenta, excreted in breast milk, protein binding 50%

PO:
Onset 30 min, peak 2-4 hr, duration 8-12 hr

IV:
Onset 5 min, peak 15 min, duration 2-4 hr

INTERACTIONS

• 
Do not use within 2 wk of MAOIs

Increase:
myocardial depression—hydantoins, general anesthetics, verapamil, class I antidysrhythmics

Increase:
tremor—tricyclic antidepressants

Increase:
hypotension—diuretics, other antihypertensives, cimetidine, nitroglycerin, alcohol, nitrates

Decrease:
effects of—sympathomimetics, lidocaine, theophylline, β-blockers, bronchodilators, xanthines

Decrease:
antihypertensive effect—NSAIDs, salicylates

Increase or decrease:
effects of—antidiabetics

Drug/Herb

Increase:
antihypertensive effect—hawthorn

Decrease:
antihypertensive effect—ephedra

Drug/Lab Test

Increase:
ANA titer, blood glucose, alk phos, LDH, AST, ALT, BUN, potassium, triglyceride, uric acid, serum lipoprotein

False increase:
urinary catecholamines

NURSING CONSIDERATIONS
Assess:

• 
Hypertension:
B/P during beginning treatment, periodically thereafter; note pulse, rate, rhythm, quality; apical/radial pulse before administration; notify prescriber of any significant changes

 
CHF: I&O, weight daily; fluid overload: weight gain, jugular venous distention, edema, crackles in lungs

 

Black Box Warning:

Abrupt discontinuation:
product should be tapered to prevent adverse reactions

• 
Baselines of renal/hepatic studies before therapy begins

Perform/provide:

• 
Storage in dry area at room temp; do not freeze

Evaluate:

• 
Therapeutic response: decreased B/P after 1-2 wk

Teach patient/family:

 

Black Box Warning:

Not to discontinue product abruptly; to taper over 2 wk; may cause precipitate angina

• 
Not to use OTC products containing α-adrenergic stimulants (nasal decongestants, OTC cold preparations) unless directed by prescriber

• 
To report bradycardia, dizziness, confusion, depression, fever

• 
To take pulse at home; advise when to notify prescriber

• 
To avoid alcohol, smoking, increased sodium intake

• 
To comply with weight control, dietary adjustments, modified exercise program

• 
To carry emergency ID to identify product, allergies

• 
To avoid hazardous activities if dizziness is present

• 
To report symptoms of CHF:
difficulty breathing, especially on exertion or when lying down; night cough; swelling of extremities

• 
To take medication at bedtime to prevent effect of orthostatic hypotension; to rise slowly

• 
To avoid driving or other hazardous activities until response is known; dizziness, drowsiness, may occur

• 
To wear support hose to minimize effects of orthostatic hypotension

TREATMENT OF OVERDOSE:

Lavage, IV glucagonor atropine for bradycardia, IV theophylline for bronchospasm; digoxin, O
2
, diuretic for cardiac failure; hemodialysis useful for removal/hypotension; administer vasopressor

Other books

Patiently Alice by Phyllis Reynolds Naylor
Only Today Part 1 by Erica Storm
Bodies of Water by T. Greenwood
Believe No One by A. D. Garrett
Labor of Love by Moira Weigel
Invaded by Melissa Landers
Manolos in Manhattan by Katie Oliver